Innovation Funding Database
Choose Your Area of Innovation:
Advanced Materials & Manufacturing
Aerospace & Spacetech
Agtech & Foodtech
Artificial Intelligence & Machines Learning
Biotech
Cleantech & Climatetech
Cybersecurity
Defensetech & Dual-Use Tech
eXtended Reality
Healthtech
Medtech
Other Tech
Quantum & Photonics
Robotics & Autonomous Systems
CDMRP: Pancreatic Cancer Research Program (PCARP)
Deadline: TBD
Funding Award Size: $300k - $1.1m
Description: The FY26 Pancreatic Cancer Research Program (PCARP) offers up to $1.1M in total costs for early detection, translational research, and novel therapeutics. Pre-announcement released February 12, 2026.
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The FY26 Pancreatic Cancer Research Program (PCARP) is anticipated to issue multiple funding opportunities to accelerate impactful research in pancreatic cancer, spanning early detection, supportive care, risk characterization, access to care, metabolic dysregulation, tumor development, biomarkers, and new therapeutics. Investigators should begin planning now—formal Funding Opportunity Announcements (FOAs), deadlines, and application requirements will be posted on Grants.gov once released. This pre-announcement does not obligate funding but signals that awards will be available in FY26.
How much funding would I receive?
Funding varies by mechanism:
Focused Pilot Award: Up to $300,000 total costs over up to 2 years.
Idea Development Award: Up to $700,000 total costs over up to 3 years (standard) or $950,000 total costs with Partnering PI Option.
Translational Research Partnership Award: Up to $1.1 million total costs over up to 3 years.
What could I use the funding for?
Funding supports research that directly addresses one or more of the following PCARP Focus Areas:
Scientific & Clinical Focus Areas
Early detection research
Identification and characterization of risk
Supportive care, quality of life, and patient perspectives
Healthcare access barriers and care delivery challenges
Metabolic disruptions (including diabetes, cachexia)
Tumor development from precursor lesions to metastasis
Biomarkers for response prediction and management strategies
Novel therapeutic targets and approaches
Each award mechanism may have specific constraints on what types of work it can support (e.g., some do not fund clinical trials or basic research).
Are there any additional benefits I would receive?
Early insight into programmatic priorities via this pre-announcement.
Access to eBRAP system for managing pre-applications.
Email subscription updates when official FOAs are released.
What is the timeline to apply and when would I receive funding?
Pre-announcement published: February 12, 2026.
Official FOAs: To be posted on Grants.gov (dates not yet announced).
Submission Deadlines: Will be specified in each FOA (pre-application and full application deadlines).
Funding Start: Following review, award negotiation, and execution (typical CDMRP cycle timing, exact months TBD).
Where does this funding come from?
PCARP is funded through the FY26 Defense Appropriations Act and managed within the Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC) as part of the Congressionally Directed Medical Research Programs (CDMRP).
Who is eligible to apply?
Eligibility depends on the award mechanism:
Focused Pilot Award: Investigators at any career level, including postdoctoral and clinical fellows.
Idea Development Award: Independent investigators at any career stage; early-career investigators may partner with experienced PIs.
Translational Research Partnership Award: Independent investigators; postdoctoral/clinical fellows are not eligible.
What companies and projects are likely to win?
Projects most competitive for PCARP will:
Directly address one or more specified focus areas with strong scientific rationale.
Demonstrate innovation and potential impact on pancreatic cancer outcomes.
Align with mechanism goals (e.g., pilot studies for early-stage ideas, partnerships for translational work).
Include appropriate preliminary data when required.
Are there any restrictions I should know about?
Focused Pilot Award: No basic research, pre-clinical animal studies, or clinical trials.
Idea Development & Translational Awards: Clinical trials and some animal work may be restricted or defined in FOA; check carefully.
Pre-proposal or letter of intent submission is required prior to full application for many mechanisms.
How long will it take me to prepare an application?
Time depends on mechanism and data readiness:
Focused Pilot Award: Plan ~4–8 weeks for a competitive pre-application and research plan.
Idea Development & Translational Awards: With required preliminary data, plan ~8–16+ weeks to assemble data, collaborators, and a strong proposal.
Start early given the expected complexity of CDMRP applications.
How can BW&CO help?
BW&CO can help you:
Interpret future FOA requirements and priorities.
Structure pre-applications/letters of intent for maximum impact.
Craft narrative, budget justification, and compliance sections.
Align scientific aims with program focus areas to increase competitiveness.
How much would BW&CO Charge?
We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.
Additional Resources
Review the solicitation here.
CDMRP: Breast Cancer Research Program (BCRP)
Deadline: TBD
Funding Award Size: $750k - $5m
Description: FY26 CDMRP Breast Cancer Research Program (BCRP) pre-announcement. Grants up to $35M for breakthrough, clinical, and consortium breast cancer research.
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The Breast Cancer Research Program (BCRP), managed by the Congressionally Directed Medical Research Programs (CDMRP), has released a Pre-Announcement for anticipated Fiscal Year 2026 (FY26) funding opportunities to support innovative, high-impact research aimed at ending breast cancer for Service Members, Veterans, their families, and the general public. This pre-announcement is intended to let investigators plan and develop proposals before the full Funding Opportunity Announcements (FOAs) are posted on Grants.gov. The government does not guarantee awards based on this document alone. FOA release dates, pre-application, and application deadlines will be announced on Grants.gov and eBRAP. Driven investigators should begin conceptualizing competitive approaches immediately.
How much funding would I receive?
The Pre-Announcement outlines anticipated award types with specified maximum total costs for FY26:
Breakthrough Award
Level 1: up to $750,000 (single PI) or $1.25M (partnering PIs)
Level 2: up to $1.65M (single PI) or $2.5M (partnering PIs)
Population Science (Level 2): up to $2.5M (single) or $3.35M (partnering)
Level 3: up to $5.6M (single) or $7M (partnering)
Level 4: up to $21M
(Breakthrough Awards range from early high-risk ideas to transformative approaches.)
Other Anticipated Mechanisms
Era of Hope Scholar Award: up to $4.9M
Clinical Research Extension Award: up to $7M (single) / $8.4M (partnering)
Transformative Breast Cancer Consortium Award: up to $35M
Transformative Breast Cancer Consortium Development Award: up to $140,000
(These awards support early-career investigators, ongoing clinical research, and large multi-project consortia.)
What could I use the funding for?
Funded research must address one or more overarching challenges critical to ending breast cancer:
Topic Areas / Research Aims
Primary prevention of breast cancer
Determinants of initiation, risk, or susceptibility
Distinguishing lethal vs. non-lethal tumors
Solutions to overdiagnosis/overtreatment
Pathways driving tumor growth and metastasis
Mechanisms of dormancy and lethal recurrence
More effective, less toxic treatments
Reducing mortality from metastatic disease
Mechanism-Specific Uses
Breakthrough Awards: high-risk/high-reward or translation-focused research
Era of Hope Scholar Award: early-career leadership and innovation
Clinical Research Extension: extending clinical data collection and analysis
Consortium Awards: integrated multi-project collaborations toward transformative goals
(Mechanism scopes will be confirmed in the FOAs.)
Are there any additional benefits I would receive?
Participating teams may benefit from:
Collaborative frameworks with consumer advocates required on some mechanisms
Access to eBRAP support and templates for submission guidance
What is the timeline to apply and when would I receive funding?
Pre-Announcement Released: February 2026 (no exact FOA deadlines yet)
FOAs and deadlines: Will be posted on Grants.gov and eBRAP once finalized.
Plan: Prepare project concepts now; watch Grants.gov and eBRAP for pre-application and application due dates, which may be weeks to months after FOA publication. Award start dates typically follow after review and appropriation obligations.
Where does this funding come from?
This funding is provided by the FY26 Defense Appropriations Act under the Department of Defense’s Congressionally Directed Medical Research Programs, specifically appropriated for breast cancer research.
Who is eligible to apply?
Eligibility varies by mechanism but generally includes:
Investigators at all academic levels or equivalent (Breakthrough, Clinical Extension)
Independent investigators (higher level awards)
Teams including consumer advocates for specified awards
Exact eligibility will be detailed in each FOA.
(Final eligibility criteria are determined in the FOAs.)
What companies and projects are likely to win?
Competitive proposals typically:
Address key overarching challenges defined by BCRP
Demonstrate innovation, clinical relevance, and impact
Include translational pathways or transformative potential
Meet mechanism-specific expectations (e.g., data access plans, interdisciplinary teams)
Are there any restrictions I should know about?
This pre-announcement is not a FOA and does not guarantee funding.
Final applications must conform to Grants.gov FOAs once released.
Mechanism specific limits on clinical trials and preliminary data requirements will be in each FOA.
How long will it take me to prepare an application?
Preparation time varies by project complexity, but given the breadth of mechanisms and expected competitive standards, begin planning now while awaiting FOAs:
Concept refinement: ~2–4 weeks
Team assembly & consumer advocate engagement: ~2–6 weeks
Budget & prelim data planning: ~4–8+ weeks depending on scope
How can BW&CO help?
BW&CO can assist with:
Translating BCRP FOA language into tailored project responses
Drafting narrative, budget justification, and impact sections
Aligning your concept with mechanism-specific review criteria
Incorporating consumer review perspectives where required
How much would BW&CO Charge?
We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.
Additional Resources
Review the solicitation here.